Abstract:
Stroke remains a leading cause for mortality and morbidity in the world despite the intense effort in research and development for remedies. Although the detailed mechanisms leading to brain tissue damage after ischemic stroke are not totally known, it is clear that inflammation plays a key role in the development of such damage. Research over the years indicates that the major players in the postischemic inflammation are inducible nitric oxide synthase (iNOS) and cyclooxygenase‐2 (COX‐2). iNOS is expressed de novo after ischemic stroke and participates in the late phase of tissue damage. Inhibition of iNOS activity or iNOS gene deletion in rodent models of ischemic stroke provides neuroprotection. COX‐2 is induced in response to ischemic and neuroexcitotoxic injuries. COX‐2 inhibition with specific inhibitors reduces brain injury caused by focal ischemia. COX‐2 gene deletion provides similar protection. Although iNOS and COX‐2 are deleterious after stroke, recent evidence indicates that these enzymes can also be beneficial. Therefore, therapeutic approaches based on iNOS and COX‐2 inhibition have to target the neurotoxic effects, while sparing the beneficial effects of the enzymes.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CBF:
-
cerebral blood flow
- C/EBP:
-
CCAAT/Enhancer Binding Protein
- COX‐1:
-
cyclooxygenase‐1
- COX‐2:
-
cyclooxygenase‐2
- COX‐3:
-
cyclooxygenase‐3
- HMG CoA:
-
(3‐hydroxy‐3‐methylglutary1)‐coenzyme A
- JNK:
-
c‐jun N‐terminal kinase
- IPC:
-
ischemic preconditioning
- LPS:
-
lipopolysaccharide
- MAPK:
-
mitogen activated protein kinase
- MCA:
-
middle cerebral artery
- NF‐IL6:
-
nuclear factor interleukin‐6
- NMDA:
-
N‐methyl‐D‐aspartic acid
- NO:
-
nitric oxide
- NOS:
-
nitric oxide synthase
- iNOS:
-
inducible NOS
- nNOS:
-
neuronal NOS
- eNOS:
-
endothelial NOS
- PARP:
-
poly(ADP‐ribose) polymerase
- PGH2:
-
prostaglandin H2
- PGG2:
-
prostaglandin G2
- PGE2:
-
prostaglandin E2
- PGI2:
-
prostaglandin I2
- PGD2:
-
prostaglandin D2
- PGF2α:
-
prostaglandin F2α
- RNA:
-
ribonucleic acid
- ROS:
-
reactive oxygen species
- SOD:
-
superoxide dismutase
- tPA:
-
tissue plasminogen activator
- UTR:
-
untranslated region
References
Akaike A, Kaneko S, Tamura Y, Nakata N, Shiomi H, et al. 1994. Prostaglandin E2 protects cultured cortical neurons against N‐methyl‐D‐aspartate receptor‐mediated glutamate cytotoxicity. Brain Res 663 (2): 237–243.
Anrather J, Iadecola C, Kawano T, Kunz A, Ross ME, et al. 2005. Mechanisms of cyclooxygenase‐2 mediated neurotoxicity. Pharmacology of cerebral ischemia. Krieglstein J, Klumpp S, editors. Medpharm Scientific Publishers, Stuttgart, Germany pp. 173-183.
Araki E, Forster C, Dubinsky J.M, Ross M.E, Iadecola C. 2001. Cyclooxygenase‐2 inhibitor ns‐398 protects neuronal cultures from lipopolysaccharide‐induced neurotoxicity. Stroke 32 (10): 2370–2375.
Arundine M, Tymianski M. 2003. Molecular mechanisms of calcium‐dependent neurodegeneration in excitotoxicity. Cell Calcium 34 (4–5):325–337.
Bal‐Price A, Brown GC. 2001. Inflammatory neurodegeneration mediated by nitric oxide from activated glia‐inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21 (17): 6480–6491.
Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, et al. 1998. Prostaglandins stimulate calcium‐dependent glutamate release in astrocytes. Nature 391: 281–285.
Bindokas VP, Jordan J, Lee CC, Miller RJ. 1996. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci 16 (4): 1324–1336.
Breder CD, Dewitt D, Kraig RP. 1995. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 355 (2): 296–315.
Breyer RM. 2001. Prostaglandin EP(1) receptor subtype selectivity takes shape. Mol Pharmacol 59 (6): 1357–1359.
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. 2001. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661–690.
Caivano M, Gorgoni B, Cohen P, Poli V. 2001. The induction of cyclooxygenase‐2 mRNA in macrophages is biphasic and requires both CCAAT enhancer‐binding protein beta (C/EBP beta) and C/EBP delta transcription factors. J Biol Chem 276 (52): 48693–48701.
Carlson NG. 2003. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase‐2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res 71 (1): 79–88.
Cazevieille C, Muller A, Meynier F, Dutrait N, Bonne C. 1994. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int 24 (4): 395–398.
Ceneviva GD, Tzeng E, Hoyt DG, Yee E, Gallagher A, et al. 1998. Nitric oxide inhibits lipopolysaccharide‐induced apoptosis in pulmonary artery endothelial cells. Am J Physiol 275 (4 Pt. 1): L717–L728.
Chan PH. 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21 (1): 2–14.
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, et al. 2002. COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99 (21): 13926–13931. Epub 2002 Sep 19.
Chen C, Magee JC, Bazan NG. 2002. Cyclooxygenase‐2 regulates prostaglandin E2 signaling in hippocampal long‐term synaptic plasticity. J Neurophysiol 87 (6): 2851–2857.
Chen CY, Shyu AB. 1994. Selective degradation of early‐response‐gene mRNAs: functional analyses of sequence features of the AU‐rich elements. Mol Cell Biol 14 (12): 8471–8482.
Cho S, Park EM, Zhou P, Frys K, Ross ME, et al. Obligatory role of inducible nitric oxide synthase in ischemic preconditioning. J Cereb Blood Flow Metab 25 (4): 493-501.
Clark RK, Lee EV, Fish CJ, White RF, Price WJ, et al. 1993. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Res Bull 31 (5): 565–572.
Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. 1997. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase‐1. J Clin Invest 99 (6): 1367–1379.
Collaco‐Moraes Y, Aspey B, Harrison M, de Belleroche J. 1996. Cyclo‐oxygenase‐2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab 16 (6): 1366–1372.
Crow JE, Beckman JS. 1995. Reactions between nitric oxide, superoxide and peroxynitrite: footprints of perxynitrite in vivo, in nitric oxide. Biochemistry, molecular biology and therapeutic implications. Ignarro L, Murad F, editors. San Diego: Academic Press; pp. 17–43.
Dawn B, Bolli R. 2002. Role of nitric oxide in myocardial preconditioning. Ann N Y Acad Sci 962: 18–41.
Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. 1994. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci USA 91 (10): 4214–4218.
Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22 (9): 391–397.
Dore S, Otsuka T, Mito T, Sugo N, Hand T, et al. 2003. Neuronal overexpression of cyclooxygenase‐2 increases cerebral infarction. Ann Neurol 54 (2): 155–162.
Dugan LL, Lin TS, He YY, Hsu CY, Choi DW. 1995. Detection of free radicals by microdialysis/spin trapping EPR following focal cerebral ischemia‐reperfusion and a cautionary note on the stability of 5,5‐dimethyl‐1‐pyrroline N‐oxide (DMPO). Free Radic Res 23 (1): 27–32.
Endres M, Laufs U, Liao JK, Moskowitz MA. 2004. Targeting eNOS for stroke protection. Trends Neurosci 27 (5): 283–289.
Forster C, Clark HB, Ross ME, Iadecola C. 1999. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol (Berl) 97 (3): 215–220.
Funk CD, Furci L, Moran N, Fitzgerald GA. 1993. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 44 (5): 934–939.
Garavito RM, Mulichak AM. 2003. The structure of mammalian cyclooxygenases. Annu Rev Biophys Biomol Struct 32: 183–206. Epub 2003 Feb 05.
Garthwaite J, Boulton CL. 1995. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57: 683–706.
Govoni S, Masoero E, Favalli L, Rozza A, Scelsi R, et al. 2001. The Cycloxygenase‐2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett 303 (2): 91–94.
Grandati M, Verrecchia C, Revaud ML, Allix M, Boulu RG, et al. 1997. Calcium‐independent NO‐synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. Br J Pharmacol 122 (4): 625–630.
Griffith OW, Stuehr DJ. 1995. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 57: 707–736.
Gross SS, Wolin MS. 1995. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 57: 737–769.
Hase S, Yokota A, Nakagiri A, Takeuchi K. 2003. Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci 74 (5): 629–641.
Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA. 2000. Cyclooxygenase‐2 contributes to N‐methyl‐D‐aspartate‐mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 293 (2): 417–425.
Huang Z, Huang PL, Ma J, Meng W, Ayata C, et al. 1996. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro‐L‐arginine. J Cereb Blood Flow Metab 16 (5): 981–987.
Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, et al. 2004. JNK‐mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101 (2): 665–670.
Hurley SD, Olschowka JA, O'Banion MK. 2002. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 19 (1): 1–15.
Iadecola C. 1997. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 20 (3): 132–139.
Iadecola C, Gorelick PB. 2005. The janus face of cyclooxygenase‐2 in ischemic stroke‐shifting toward downstream targets. Stroke 36 (2): 182-185.
Iadecola C, Cho S, Feuerstein GZ, Hallenbeck JM. 2004. Inflammation. Stroke: pathophysiology, diagnosis, and management. Wolf P, editor. New York: Churchill Livingston.
Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. 1999. Cyclooxygenase‐2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol (Berl) 98 (1): 9–14.
Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, et al. 2001. Reduced susceptibility to ischemic brain injury and N‐methyl‐D‐aspartate‐mediated neurotoxicity in cyclooxygenase‐2‐deficient mice. Proc Natl Acad Sci USA 98 (3): 1294–1299.
Iadecola C, Xu X, Zhang F, el‐Fakahany EE, Ross ME. 1995a. Marked induction of calcium‐independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb Blood Flow Metab 15 (1): 52–59.
Iadecola C, Zhang F, Xu S, Casey R, Ross ME. 1995b. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15 (3): 378–384.
Iadecola C, Zhang F, Xu X. 1995c. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 268 (1 Pt. 2): R286–R292.
Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. 1996. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 27 (8): 1373–1380.
Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. 1997. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 17 (23): 9157–9164.
Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. 1996. COX‐2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93 (6): 2317–2321.
Kawano T, Anrather J, Frys K, Zhou P, Iadecola C. 2004. Activation of prostagladin EP1 receptors contributes to COX‐2 dependent neruotoxicity. Society for Neuroscience 2004 Annual Meeting Abstract, 600.8.
Kelley KA, Ho L, Winger D, Freire‐ Moar J, Borelli CB, et al. 1999. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase‐2. Am J Pathol 155 (3): 995–1004.
Kim GW, Kondo T, Noshita N, Chan PH. 2002. Manganese superoxide dismutase deficiency exacerbates cerebral infarction after focal cerebral ischemia/reperfusion in mice: implications for the production and role of superoxide radicals. Stroke 33 (3): 809–815.
Kim YM, Talanian RV, Billiar TR. 1997. Nitric oxide inhibits apoptosis by preventing increases in caspase‐3‐like activity via two distinct mechanisms. J Biol Chem 272 (49): 31138–31148.
Kinouchi H, Epstein CJ, Mizui T, Carlson E, Chen SF, et al. 1991. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci USA 88 (24): 11158–11162.
Kobayashi T, Narumiya S. 2002. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 68–69: 557–573.
Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K, et al. 1997. Reduction of CuZn‐superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 17 (11): 4180–4189.
Lapchak PA, Araujo DM, Song D, Zivin JA. 2001. Neuroprotection by the selective cyclooxygenase‐2 inhibitor SC‐236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 32 (5): 1220–1225.
Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, et al. 2000. Regulation of cyclooxygenase 2 mRNA stability by the mitogen‐activated protein kinase p38 signaling cascade. Mol Cell Biol 20 (12): 4265–4274.
Lee JM, Grabb MC, Zipfel GJ, Choi DW. 2000. Brain tissue responses to ischemia. J Clin Invest 106 (6): 723–731.
Licinio J, Wong ML. 1997. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 100 (12): 2941–2947.
Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY. 1989. Polyethylene glycol‐conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256 (2 Pt. 2): H589–H593.
Lo EH, Dalkara T, Moskowitz MA. 2003. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4 (5): 399–415.
Love S. 1999. Oxidative stress in brain ischemia. Brain Pathol 9 (1): 119–131.
Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, et al. 2003. Coordinate activation of HIF‐1 and NF‐κB DNA binding and COX‐2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 44 (10): 4163–4170.
Mackensen GB, Patel M, Sheng H, Calvi CL, Batinic‐ Haberle I, et al. 2001. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J Neurosci 21 (13): 4582–4592.
Mac Micking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, et al. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81 (4): 641–650.
Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, et al. 2004. Prostanoids, not reactive oxygen species, mediate COX‐2‐dependent neurotoxicity. Ann Neurol 55 (5): 668–675.
Mander P, Brown GC. 2004. Nitric oxide, hypoxia and brain inflammation. Biochem Soc Trans 32 (Pt. 6): 1068–1069.
Mander P, Borutaite V, Moncada S, Brown GC. 2005. Nitric oxide from inflammatory‐activated glia synergizes with hypoxia to induce neuronal death. J Neurosci Res 79 (1–2): 208–215.
Mannick JB, Miao XQ, Stamler JS. 1997. Nitric oxide inhibits Fas‐induced apoptosis. J Biol Chem 272 (39): 24125–24128.
Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, et al. 2001. S‐Nitrosylation of mitochondrial caspases. J Cell Biol 154 (6): 1111–1116. Epub 2001 Sep 10.
McCullough L, Wu L, Haughey N, Liang X, Hand T, et al. 2004. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24 (1): 257–268.
Miettinen S, Fusco FR, Yrjanheikki J, Keinanen R, Hirvonen T, et al. 1997. Spreading depression and focal brain ischemia induce cyclooxygenase‐2 in cortical neurons through N‐methyl‐D‐aspartic acid‐receptors and phospholipase A2. Proc Natl Acad Sci USA 94 (12): 6500–6505.
Mirjany M, Ho L, Pasinetti GM. 2002. Role of cyclooxygenase‐2 in neuronal cell cycle activity and glutamate‐mediated excitotoxicity. J Pharmacol Exp Ther 301 (2): 494–500.
Morimoto T, Globus MY, Busto R, Martinez E, Ginsberg MD. 1996. Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 16 (1): 92–99.
Murakami K, Kondo T, Kawase M, Li Y, Sato S, et al. 1998. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci 18 (1): 205–213.
Nagayama M, Zhang F, Iadecola C. 1998. Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J Cereb Blood Flow Metab 18 (10): 1107–1113.
Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, et al. 1998. Cyclooxygenase‐2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 95 (18): 10954–10959.
Nathan C. 1997. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100 (10): 2417–2423.
Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. 2000. Cyclooxygenase‐2 contributes to functional hyperemia in whisker‐barrel cortex. J Neurosci 20 (2): 763–770.
Nogawa S, Zhang F, Ross ME, Iadecola C. 1997. Cyclo‐oxygenase‐2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17 (8): 2746–2755.
Oka T, Oka K, Kobayashi T, Sugimoto Y, Ichikawa A, et al. 2003. Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. J Physiol 551 (Pt. 3): 945–954.
Park EM, Cho S, Frys K, Racchumi G, Zhou P, et al. 2004. Interaction between inducible nitric oxide synthase and poly(ADP‐ribose) polymerase in focal ischemic brain injury. Stroke 35 (12): 2896–2901.
Park KM, Byun JY, Kramers C, Kim JI, Huang PL, et al. 2003. Inducible nitric‐oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem 278 (29): 27256–27266. Epub 2003 Apr 07.
Parmentier S, Bohme GA, Lerouet D, Damour D, Stutzmann JM, et al. 1999. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 127 (2): 546–552.
Parmentier‐Batteur S, Bohme GA, Lerouet D, Zhou‐Ding L, Beray V, et al. 2001. Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia‐induced brain injury. J Cereb Blood Flow Metab 21 (1): 15–21.
Peters O, Back T, Lindauer U, Busch C, Megow D, et al. 1998. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 18 (2): 196–205.
Piantadosi CA, Zhang J. 1996. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat. Stroke 27 (2): 327–331.
Sairanen T, Ristimaki A, Karjalainen‐Lindsberg ML, Paetau A, Kaste M, et al. 1998. Cyclooxygenase‐2 is induced globally in infarcted human brain. Ann Neurol 43 (6): 738–747.
Samdani AF, Dawson TM, Dawson VL. 1997. Nitric oxide synthase in models of focal ischemia. Stroke 28 (6): 1283–1288.
Sasaki T, Kitagawa K, Yamagata K, Takemiya T, Tanaka S, et al. 2004. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase‐2‐deficient mice. J Cereb Blood Flow Metab 24 (1): 107–113.
Smith WL, Song I. 2002. The enzymology of prostaglandin endoperoxide H synthases‐1 and ‐2. Prostaglandins Other Lipid Mediat 68–69: 115–128.
Stamler JS. 1994. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78 (6): 931–936.
Suganami T, Mori K, Tanaka I, Mukoyama M, Sugawara A, et al. 2003. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42 (6): 1183–1190.
Sugawara T, Chan PH. 2003. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid Redox Signal 5 (5): 597–607.
Sugimoto K, Iadecola C. 2003. Delayed effect of administration of COX‐2 inhibitor in mice with acute cerebral ischemia. Brain Res 960 (1–2): 273–276.
Takadera T, Shiraishi Y, Ohyashiki T. 2004. Prostaglandin E2 induced caspase‐dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int 45 (5): 713–719.
Takahashi K, Greenberg JH, Jackson P, Maclin K, Zhang J. 1997. Neuroprotective effects of inhibiting poly(ADP‐ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17 (11): 1137–1142.
Tarpey MM, Wink DA, Grisham MB. 2004. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 286 (3): R431–R444.
Thornhill J, Smith M. 1998. Intracerebroventricular prostaglandin administration increases the neural damage evoked by global hemispheric hypoxic ischemia. Brain Res 784 (1–2): 48–56.
tPA Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group. N Engl J Med 333 (24): 1581-1587.
Traystman RJ, Kirsch JR, Koehler RC. 1991. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 71 (4): 1185–1195.
Tsuboi K, Sugimoto Y, Ichikawa A. 2002. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68–69: 535–556.
Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, et al. 1998. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281–284.
Virag L, Szabo C. 2002. The therapeutic potential of poly(ADP‐ribose) polymerase inhibitors. Pharmacol Rev 54 (3): 375–429.
Vodovotz Y, Kwon NS, Pospischil M, Manning J, Paik J, et al. 1994. Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with IFN‐gamma and bacterial lipopolysaccharide. J Immunol 152 (8): 4110–4118.
Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. 2000. Transcriptional activation of the cyclooxygenase‐2 gene in endotoxin‐treated RAW 264.7 macrophages. J Biol Chem 275 (9): 6259–6266.
Wang H, Hitron IM, Iadecola C, Pickel VM. 2004. Synaptic and vascular associations of neurons containing cyclooxygenase‐2 and nitric oxide synthase in rat somatosensory cortex. Cereb Cortex 22: 22.
Yokota C, Kuge Y, Inoue H, Tagaya M, Kito G, et al. 2003. Post‐ischemic cyclooxygenase‐2 expression is regulated by the extent of cerebral blood flow reduction in non‐human primates. Neurosci Lett 341 (1): 37–40.
Zhao X, Haensel C, Araki E, Ross ME, Iadecola C. 2000. Gene‐dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 872 (1–2): 215–218.
Zhou P, Qian L, Iadecola C. 2005. Nitric oxide inhibits caspase activation and apoptotic morphology but does not rescue neuronal death. J Cereb Blood Flow Metab 25 (3): 348-357.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this entry
Cite this entry
Zhou, P., Iadecola, C. (2007). iNOS and COX‐2 in Ischemic Stroke. In: Lajtha, A., Chan, P.H. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-30383-3_3
Download citation
DOI: https://doi.org/10.1007/978-0-387-30383-3_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-30352-9
Online ISBN: 978-0-387-30383-3
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences